Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 98

1.

Pauses in compressions during pediatric CPR: Opportunities for improving CPR quality.

O'Connell KJ, Keane RR, Cochrane NH, Sandler AB, Donoghue AJ, Kerrey BT, Myers SR, Vazifedan T, Mullan PC.

Resuscitation. 2019 Aug 14. pii: S0300-9572(19)30575-1. doi: 10.1016/j.resuscitation.2019.08.015. [Epub ahead of print]

PMID:
31421191
2.

Process conformance is associated with successful first intubation attempt and lower odds of adverse events in a paediatric emergency setting.

O'Connell KJ, Yang S, Cheng M, Sandler AB, Cochrane NH, Yang J, Webman RB, Marsic I, Burd R.

Emerg Med J. 2019 Sep;36(9):520-528. doi: 10.1136/emermed-2018-208133. Epub 2019 Jul 18.

PMID:
31320332
3.

Videographic Assessment of the Quality of EMS to ED Handoff Communication During Pediatric Resuscitations.

Sumner BD, Grimsley EA, Cochrane NH, Keane RR, Sandler AB, Mullan PC, O'Connell KJ.

Prehosp Emerg Care. 2019 Jan-Feb;23(1):15-21. doi: 10.1080/10903127.2018.1481475. Epub 2018 Aug 30.

PMID:
30118642
4.

Isolating the Role of Bevacizumab in Elderly Patients With Previously Untreated Nonsquamous Non-Small Cell Lung Cancer: Secondary Analyses of the ECOG 4599 and PointBreak Trials.

Langer CJ, Socinski MA, Patel JD, Sandler AB, Schiller JH, Leon L, Hazard SJ, Ramalingam SS.

Am J Clin Oncol. 2016 Oct;39(5):441-7. doi: 10.1097/COC.0000000000000163.

5.

Baseline tumour measurements predict survival in advanced non-small cell lung cancer.

Gerber DE, Dahlberg SE, Sandler AB, Ahn DH, Schiller JH, Brahmer JR, Johnson DH.

Br J Cancer. 2013 Sep 17;109(6):1476-81. doi: 10.1038/bjc.2013.472. Epub 2013 Aug 13.

6.

Body mass index and its association with clinical outcomes for advanced non-small-cell lung cancer patients enrolled on Eastern Cooperative Oncology Group clinical trials.

Dahlberg SE, Schiller JH, Bonomi PB, Sandler AB, Brahmer JR, Ramalingam SS, Johnson DH.

J Thorac Oncol. 2013 Sep;8(9):1121-7. doi: 10.1097/JTO.0b013e31829cf942.

7.

EGFR tyrosine kinase inhibitors: difference in efficacy and resistance.

Robinson KW, Sandler AB.

Curr Oncol Rep. 2013 Aug;15(4):396-404. doi: 10.1007/s11912-013-0323-7. Review.

PMID:
23674236
8.

The role of MET receptor tyrosine kinase in non-small cell lung cancer and clinical development of targeted anti-MET agents.

Robinson KW, Sandler AB.

Oncologist. 2013;18(2):115-22. doi: 10.1634/theoncologist.2012-0262. Epub 2013 Jan 23. Review.

9.

Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer.

Soria JC, Mauguen A, Reck M, Sandler AB, Saijo N, Johnson DH, Burcoveanu D, Fukuoka M, Besse B, Pignon JP; meta-analysis of bevacizumab in advanced NSCLC collaborative group.

Ann Oncol. 2013 Jan;24(1):20-30. doi: 10.1093/annonc/mds590. Epub 2012 Nov 23. Review. Erratum in: Ann Oncol. 2013 Apr;24(4):1133.

PMID:
23180113
10.

Prognostic models to predict survival in non-small-cell lung cancer patients treated with first-line paclitaxel and carboplatin with or without bevacizumab.

Hoang T, Dahlberg SE, Sandler AB, Brahmer JR, Schiller JH, Johnson DH.

J Thorac Oncol. 2012 Sep;7(9):1361-8. doi: 10.1097/JTO.0b013e318260e106.

11.

Rationale and design of MARQUEE: a phase III, randomized, double-blind study of tivantinib plus erlotinib versus placebo plus erlotinib in previously treated patients with locally advanced or metastatic, nonsquamous, non-small-cell lung cancer.

Scagliotti GV, Novello S, Schiller JH, Hirsh V, Sequist LV, Soria JC, von Pawel J, Schwartz B, Von Roemeling R, Sandler AB.

Clin Lung Cancer. 2012 Sep;13(5):391-5. doi: 10.1016/j.cllc.2012.01.003. Epub 2012 Mar 21.

PMID:
22440336
12.

Beyond bevacizumab: antiangiogenic agents.

Rogosin S, Sandler AB.

Clin Lung Cancer. 2012 Sep;13(5):326-33. doi: 10.1016/j.cllc.2011.12.001. Epub 2012 Jan 31. Review.

PMID:
22297207
13.

Differential effect of age on survival in advanced NSCLC in women versus men: analysis of recent Eastern Cooperative Oncology Group (ECOG) studies, with and without bevacizumab.

Wakelee HA, Dahlberg SE, Brahmer JR, Schiller JH, Perry MC, Langer CJ, Sandler AB, Belani CP, Johnson DH; Eastern Cooperative Oncology Group.

Lung Cancer. 2012 Jun;76(3):410-5. doi: 10.1016/j.lungcan.2011.12.006. Epub 2012 Jan 21.

14.

Phase III clinical trial development: a process of chutes and ladders.

Dilts DM, Cheng SK, Crites JS, Sandler AB, Doroshow JH.

Clin Cancer Res. 2010 Nov 15;16(22):5381-9. doi: 10.1158/1078-0432.CCR-10-1273. Epub 2010 Nov 9.

15.

Long-term outcome of a phase II study of docetaxel-based multimodality chemoradiotherapy for locally advanced carcinoma of the esophagus or gastroesophageal junction.

Choong NW, Mauer AM, Haraf DC, Ferguson MK, Sandler AB, Kesler KA, Fishkin PA, Ansari RH, Wade J 3rd, Krauss SA, Sciortino DF, Posner MC, Kocherginsky M, Hoffman PC, Szeto L, Vokes EE.

Med Oncol. 2011 Dec;28 Suppl 1:S152-61. doi: 10.1007/s12032-010-9658-1. Epub 2010 Aug 21.

PMID:
20730572
16.

Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599.

Dahlberg SE, Sandler AB, Brahmer JR, Schiller JH, Johnson DH.

J Clin Oncol. 2010 Feb 20;28(6):949-54. doi: 10.1200/JCO.2009.25.4482. Epub 2010 Jan 19.

17.

Prognostic factors for resected non-small cell lung cancer with pN2 status: implications for use of postoperative radiotherapy.

Moretti L, Yu DS, Chen H, Carbone DP, Johnson DH, Keedy VL, Putnam JB Jr, Sandler AB, Shyr Y, Lu B.

Oncologist. 2009 Nov;14(11):1106-15. doi: 10.1634/theoncologist.2009-0130. Epub 2009 Nov 6.

18.

Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: Eastern Cooperative Oncology Group Study E3501.

Horn L, Dahlberg SE, Sandler AB, Dowlati A, Moore DF, Murren JR, Schiller JH.

J Clin Oncol. 2009 Dec 10;27(35):6006-11. doi: 10.1200/JCO.2009.23.7545. Epub 2009 Oct 13.

19.

A phase II study of concurrent chemoradiation with weekly docetaxel, carboplatin, and radiation therapy followed by consolidation chemotherapy with docetaxel and carboplatin for locally advanced inoperable non-small cell lung cancer (NSCLC).

Jain AK, Hughes RS, Sandler AB, Dowlati A, Schwartzberg LS, Dobbs T, Schlabach L, Wu J, Muldowney NJ, Choy H.

J Thorac Oncol. 2009 Jun;4(6):722-7. doi: 10.1097/JTO.0b013e3181a5275c.

20.

Emerging data with antiangiogenic therapies in early and advanced non-small-cell lung cancer.

Horn L, Sandler AB.

Clin Lung Cancer. 2009 Mar;10 Suppl 1:S7-16. doi: 10.3816/CLC.2009.s.002. Review.

21.

Angiogenesis in the treatment of non-small cell lung cancer.

Horn L, Sandler AB.

Proc Am Thorac Soc. 2009 Apr 15;6(2):206-17. doi: 10.1513/pats.200807-066LC. Review.

22.

Beyond doublet chemotherapy for advanced non-small-cell lung cancer: combination of targeted agents with first-line chemotherapy.

Herbst RS, Lynch TJ, Sandler AB.

Clin Lung Cancer. 2009 Jan;10(1):20-7. doi: 10.3816/CLC.2009.n.003. Review.

PMID:
19289368
23.

A phase II study of celecoxib in combination with paclitaxel, carboplatin, and radiotherapy for patients with inoperable stage IIIA/B non-small cell lung cancer.

Mutter R, Lu B, Carbone DP, Csiki I, Moretti L, Johnson DH, Morrow JD, Sandler AB, Shyr Y, Ye F, Choy H.

Clin Cancer Res. 2009 Mar 15;15(6):2158-65. doi: 10.1158/1078-0432.CCR-08-0629. Epub 2009 Mar 10.

24.

Steps and time to process clinical trials at the Cancer Therapy Evaluation Program.

Dilts DM, Sandler AB, Cheng SK, Crites JS, Ferranti LB, Wu AY, Finnigan S, Friedman S, Mooney M, Abrams J.

J Clin Oncol. 2009 Apr 10;27(11):1761-6. doi: 10.1200/JCO.2008.19.9133. Epub 2009 Mar 2.

25.

Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmonary hemorrhage in first-line advanced, unresectable non-small-cell lung cancer treated with Carboplatin and Paclitaxel plus bevacizumab.

Sandler AB, Schiller JH, Gray R, Dimery I, Brahmer J, Samant M, Wang LI, Johnson DH.

J Clin Oncol. 2009 Mar 20;27(9):1405-12. doi: 10.1200/JCO.2008.16.2412. Epub 2009 Feb 17. Erratum in: J Clin Oncol. 2009 Jul 10;27(20):3410.

26.

Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer.

Heymach JV, Paz-Ares L, De Braud F, Sebastian M, Stewart DJ, Eberhardt WE, Ranade AA, Cohen G, Trigo JM, Sandler AB, Bonomi PD, Herbst RS, Krebs AD, Vasselli J, Johnson BE.

J Clin Oncol. 2008 Nov 20;26(33):5407-15. doi: 10.1200/JCO.2008.17.3138. Epub 2008 Oct 20.

PMID:
18936474
27.

A phase II multicenter study of L-alanosine, a potent inhibitor of adenine biosynthesis, in patients with MTAP-deficient cancer.

Kindler HL, Burris HA 3rd, Sandler AB, Oliff IA.

Invest New Drugs. 2009 Feb;27(1):75-81. doi: 10.1007/s10637-008-9160-1. Epub 2008 Jul 11.

PMID:
18618081
28.

Randomized phase III trial comparing single-agent paclitaxel Poliglumex (CT-2103, PPX) with single-agent gemcitabine or vinorelbine for the treatment of PS 2 patients with chemotherapy-naïve advanced non-small cell lung cancer.

O'Brien ME, Socinski MA, Popovich AY, Bondarenko IN, Tomova A, Bilynsky BT, Hotko YS, Ganul VL, Kostinsky IY, Eisenfeld AJ, Sandalic L, Oldham FB, Bandstra B, Sandler AB, Singer JW.

J Thorac Oncol. 2008 Jul;3(7):728-34. doi: 10.1097/JTO.0b013e31817c6b68.

29.

A phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomas.

Gore L, Rothenberg ML, O'Bryant CL, Schultz MK, Sandler AB, Coffin D, McCoy C, Schott A, Scholz C, Eckhardt SG.

Clin Cancer Res. 2008 Jul 15;14(14):4517-25. doi: 10.1158/1078-0432.CCR-07-1461. Epub 2008 Jun 25.

30.

Phase I trial of pemetrexed plus oxaliplatin administered every other week in patients with metastatic cancer.

Stover DG, Lockhart AC, Berlin JD, Chan E, Sandler AB, Sosman JA, Middlebrook V, Nicol S, Rothenberg ML.

Invest New Drugs. 2008 Aug;26(4):339-45. doi: 10.1007/s10637-008-9133-4. Epub 2008 May 8.

PMID:
18463792
31.

Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib.

Miller VA, Riely GJ, Zakowski MF, Li AR, Patel JD, Heelan RT, Kris MG, Sandler AB, Carbone DP, Tsao A, Herbst RS, Heller G, Ladanyi M, Pao W, Johnson DH.

J Clin Oncol. 2008 Mar 20;26(9):1472-8. doi: 10.1200/JCO.2007.13.0062.

PMID:
18349398
33.

Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599.

Ramalingam SS, Dahlberg SE, Langer CJ, Gray R, Belani CP, Brahmer JR, Sandler AB, Schiller JH, Johnson DH; Eastern Cooperative Oncology Group.

J Clin Oncol. 2008 Jan 1;26(1):60-5. doi: 10.1200/JCO.2007.13.1144.

PMID:
18165641
34.

Treatment of non-small cell lung cancer, stage IV: ACCP evidence-based clinical practice guidelines (2nd edition).

Socinski MA, Crowell R, Hensing TE, Langer CJ, Lilenbaum R, Sandler AB, Morris D; American College of Chest Physicians.

Chest. 2007 Sep;132(3 Suppl):277S-289S.

PMID:
17873174
35.

Inhibition of angiogenesis in the treatment of non-small cell lung cancer.

Keedy VL, Sandler AB.

Cancer Sci. 2007 Dec;98(12):1825-30. Epub 2007 Sep 24. Review.

36.

Novel agents in the treatment of lung cancer: Fourth Cambridge Conference.

Lynch TJ, Bonomi PD, Butts C, Davies AM, Engelman J, Govindan R, Herbst RS, Heymach JV, Johnson BE, Martins RG, Perez-Soler R, Riely GJ, Sandler AB, Sequist LV, Socinski MA, Wong KK, Hart CS.

Clin Cancer Res. 2007 Aug 1;13(15 Pt 2):s4583-8.

37.

Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non small-cell lung cancer whose tumors have failed first-line platinum-based chemotherapy.

Vansteenkiste J, Lara PN Jr, Le Chevalier T, Breton JL, Bonomi P, Sandler AB, Socinski MA, Delbaldo C, McHenry B, Lebwohl D, Peck R, Edelman MJ.

J Clin Oncol. 2007 Aug 10;25(23):3448-55. Epub 2007 Jul 2. Erratum in: J Clin Oncol. 2007 Nov 20;25(33):5339. Edelman, Mark [corrected to Edelman, Martin J].

PMID:
17606973
38.

The rationale for adjuvant chemotherapy in stage I non-small cell lung cancer.

Horn L, Sandler AB, Putnam JB Jr, Johnson DH.

J Thorac Oncol. 2007 May;2(5):377-83.

39.

Systemic therapy of bronchioloalveolar carcinoma: results of the first IASLC/ASCO consensus conference on bronchioloalveolar carcinoma.

Kris MG, Giaccone G, Davies A, Fukuoka M, Garfield DH, Jassem J, Quoix EA, Sandler AB, Scagliotti GV, Van Meerbeeck JP, West H.

J Thorac Oncol. 2006 Nov;1(9 Suppl):S32-6.

40.

Survival differences by sex for patients with advanced non-small cell lung cancer on Eastern Cooperative Oncology Group trial 1594.

Wakelee HA, Wang W, Schiller JH, Langer CJ, Sandler AB, Belani CP, Johnson DH; Eastern Cooperative Oncology Group.

J Thorac Oncol. 2006 Jun;1(5):441-6.

41.

Processes to activate phase III clinical trials in a Cooperative Oncology Group: the Case of Cancer and Leukemia Group B.

Dilts DM, Sandler AB, Baker M, Cheng SK, George SL, Karas KS, McGuire S, Menon GS, Reusch J, Sawyer D, Scoggins M, Wu A, Zhou K, Schilsky RL; Case of Cancer and Leukemia Group B.

J Clin Oncol. 2006 Oct 1;24(28):4553-7.

PMID:
17008694
43.

Summary statement: novel agents in the treatment of lung cancer: advances in epidermal growth factor receptor-targeted agents.

Lynch TJ, Adjei AA, Bunn PA Jr, Eisen TG, Engelman J, Goss GD, Haber DA, Heymach JV, Jänne PA, Johnson BE, Johnson DH, Lilenbaum RC, Meyerson M, Sandler AB, Sequist LV, Settleman J, Wong KK, Hart CS.

Clin Cancer Res. 2006 Jul 15;12(14 Pt 2):4365s-4371s. No abstract available.

44.
45.

Advanced non-small-cell lung cancer: new data, therapy choices, and challenging decisions.

Sandler AB.

Oncology (Williston Park). 2006 May;20(6):626-8. Review. No abstract available.

46.

Nondermatologic adverse events associated with anti-EGFR therapy.

Sandler AB.

Oncology (Williston Park). 2006 Apr;20(5 Suppl 2):35-40. Review.

47.

The safety of bevacizumab.

Sanborn RE, Sandler AB.

Expert Opin Drug Saf. 2006 Mar;5(2):289-301. Review.

PMID:
16503749
48.

Targeting angiogenesis in lung cancer.

Sandler AB.

Semin Oncol. 2005 Dec;32(6 Suppl 10):S16-22. Review.

PMID:
16459175
49.

First-line treatment for advanced non-small-cell lung cancer.

Laskin JJ, Sandler AB.

Oncology (Williston Park). 2005 Nov;19(13):1671-6; discussion 1678-80. Review.

50.

The role of prophylactic cranial radiation in the treatment of non-small-cell lung cancer.

Laskin JJ, Sandler AB.

Clin Adv Hematol Oncol. 2003 Dec;1(12):731-34. Review.

PMID:
16258477

Supplemental Content

Loading ...
Support Center